Entity

Rejuversen S.L.

Biotechnology - Therapeutics and Diagnostics

Rejuversen S.L.´s lead program is based on the development of a novel therapy that promotes immune-mediated clearance of senescent cells from tumors.

This strategy will be translated into a first-in-human proof-of-concept for therapies based on senescent cell clearance that will extend into diseases associated with aging.

Rejuversen S.L. is also building a discovery programs focused on identifying novel sensecence associated targets in various age-related disorders through screening-based approaches.